Risankizumab for the treatment of moderate to severe psoriasis: impact on health-related quality of life and psychological wellbeing

Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Risankizumab (RZB) is a humanized monoclonal antibody that specifically blocks the p19 subunit of interleukin 23, which in turn regulates the activation, differentiation, and survival of Th17. RZB has proved their efficacy and their safety compared to anti-TNF. However, studies that assess and compare the improvement in other secondary PROs such as the patient's quality of life are still scarce. Health-related quality of life (HRQoL) is the sum of physical health, well-being, and participation; it defines the functional effect of a disease or its treatment and how it is perceived by the patient. The objective of this paper is to analyze the literature on the impact of treatment with RZB on the quality of life of patients with PSO and their psychological well-being. A bibliographic search was carried out to identify all the papers published from July 2015 to June 1, 2022, on RZB treatment in psoriasis and its impact on health-related quality of life and psychological well-being, finally twenty articles have been evaluated in full text, of which 8 were excluded because they did not meet the inclusion criteria. Risankizumab has shown not only to have very relevant data on effectiveness and safety, but all of this is associated with an improvement in quality of life related to health and psychological well-being measured on generic and specific quality of life scales, both in pivotal trials, ad hoc analysis, and data in real clinical practice

Fully home-based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study

Methyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT) is highly effi-cacious for the treatment of nonhyperkeratotic actinic keratosis (AK), even when par-tially performed at home. To evaluate the long-term effectiveness, safety, andpatient-reported outcomes of MAL DL-PDT performed completely by the patient inreal life conditions. An open prospective study was conducted in Spain amongpatients diagnosed with at least five AK lesions on the face or the scalp. Patientsreceived instruction and information in infographic format to perform MAL DL-PDTat home. All had been treated with 30% urea daily for 7 days before the day of MALDL-PDT. Meteorological conditions on the day of the treatment and adverse effectswere recorded. Patients underwent follow-up, and a second session of home-basedMAL DL-PDT if deemed necessary, 3, 6, and 12 months after the initial treatmentsession. The study population consisted of 22 patients (19 men and three women,mean [standard deviation, SD] age, 72.05 [6.96] years). A complete response wasobserved in 47.7% of AK lesions at 3 months (p< 0.001) and 65.9% (n=199) at12 months (p< 0.001). Olsen grade II lesions showed the highest rate of response(76.07% at 12 months). The mean (SD) actinic keratosis area and severity index scoredecreased significantly from 4.99 (2.43) at baseline to 2.33 (1.01) at 12 months(p=0.0234). Adverse effects were mild and expected. A majority of patients were“satisfied”or“very satisfied”with the treatment instruction provided (90.9%) andthe treatment outcome (72.7%). MAL DL-PDT can be applied at home like any othertopical treatment for AK. Our results indicate good long-term effectiveness, a highlevel of patient satisfaction, and no significant side effect